News Archives - Page 3 of 712

ThursdayAug 07, 2025 9:45 am

D-Wave Quantum Inc. (NYSE: QBTS): 27% of Surveyed Business Leaders Expect $5M+ ROI from Quantum Optimization Within First Year

Survey by Wakefield Research and D-Wave shows 46% of surveyed business leaders expect $1 million to $5 million ROI from quantum optimization within the first year of adoption. 81% believe they have reached the limits of classical computing’s capabilities for optimization. 53% are planning to integrate quantum computing into their workflows, while 27% are considering it. Quantum optimization is seen as especially valuable in logistics, supply chain, manufacturing, planning and inventory, and R&D. 88% of participants said their organizations would “go above and beyond” for even a 5% improvement in optimization. A new survey released by D-Wave Quantum Inc. (NYSE:…

WednesdayAug 06, 2025 12:10 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies. The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer. A review of 221 clinical trials informed the development of the predictive algorithm. Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes. Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine…

WednesdayAug 06, 2025 11:30 am

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings. The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation. Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://ibn.fm/0TAG4). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system…

WednesdayAug 06, 2025 10:10 am

Bollinger Innovations Inc. (NASDAQ: BINI) Drives Commercial EV Leadership with Bold Rebrand, Market Clarity

Mullen Automotive recently brought all of its EV products and brands together under one strong and unified identity — Bollinger Innovations. The pivot to one commercial EV brand comes amid mounting demand for electrification in delivery, logistics and municipal vehicle fleets. The company’s new identity is also trading under new Nasdaq stock symbol NASDAQ: BINI. The company’s move under one brand clarifies market positioning, creating cohesion across product lines ready to service the commercial vehicle industry. Bollinger Innovations (NASDAQ: BINI), formerly known as Mullen Automotive, has completed a major corporate transformation, officially rebranding and switching its NASDAQ ticker from MULN to…

WednesdayAug 06, 2025 9:50 am

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal…

WednesdayAug 06, 2025 9:10 am

QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Applauds FAA Proposal to Normalize BVLOS Drone Operations

Safe Pro Group (NASDAQ: SPAI), a leader in AI-powered defense and security solutions, welcomed the FAA’s proposed rules to streamline Beyond Visual Line of Sight (BVLOS) drone operations. The Company expects the move will accelerate adoption of its computer vision and object detection technologies across government, public, and commercial sectors. Safe Pro’s Airborne Response unit is a top provider of drone-based infrastructure inspections in Florida, and its AI technology has been field-tested in Ukraine to detect landmines and threats with high-speed accuracy. The Company is integrating these capabilities to expand services in public safety, disaster response, and environmental protection. To…

TuesdayAug 05, 2025 11:15 am

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Two newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology. The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from three noncoplanar directions. The second patent covers the company’s rhythm analysis algorithm by continuously analyzing signal input. HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://ibn.fm/6xni4). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S.…

TuesdayAug 05, 2025 10:30 am

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Set to Leverage Proprietary Tech, New Trade Deals as Magnetic Materials Gatekeeper

Recent White House announcements with EU and Japan outline tariff guidelines, investment commitments. The confluence of trade policy and industrial investment creates a strategic trade windfall for U.S. critical minerals. Ucore’s proprietary RapidSX technology offers a compelling supply chain solution. Recent trade agreements with the European Union and Japan are unlocking massive investment that could reshape U.S. manufacturing, particularly for critical components such as permanent magnet materials. Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) and its RapidSX(TM) separation technology are strategically positioned to become the North American gatekeeper for magnet-grade rare earth oxides under this new industrial paradigm. Under President…

TuesdayAug 05, 2025 9:45 am

AI Maverick Intel Inc. (BINP): The AI Platform That Might Just Replace Your SDR Team

AI Maverick’s next-gen platform can replicate human-like sales conversations—handling prospecting, objections, and scheduling with no SDR required Recent rollout includes adaptive language models, real-time buying signal detection, and multi-step consultative selling automation Company rebrand reflects shift from biotech to AI-led customer acquisition across sectors like healthcare, transportation, and insurance In a world where sales teams are expected to scale faster than ever, often with fewer resources, the rise of intelligent automation platforms is beginning to redefine how companies engage with prospects. For years, sales development representatives (“SDRs”) have filled the gap between marketing and revenue, conducting outreach, asking discovery questions,…

TuesdayAug 05, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company Nutriband’s recent 25% preferred stock dividend uniquely ties shareholder reward to regulatory achievement CEO notes that “core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA(TM) Fentanyl” Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug's safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable…

Site Search

Company Search

Category: News